Plasminogen supplementation reverses fibrinolytic insufficiency in sepsis-induced disseminated intravascular coagulation: a pilot study
Authors' conclusion
Plasminogen supplementation restores fibrinolytic capacity, supporting its therapeutic potential in sepsis-induced DIC.
Study context
- Population
- Patients with sepsis-induced coagulopathy
- Participants
- 60 patients
- Comparison
- OctaplasLG® vs placebo
- Primary endpoint
- Change in functional plasminogen and plasmin generation (pre- to post-infusion)
Methodological detailsplacebo-controlled, pilot study, parallel murine model of septic disseminated intravascular coagulation (DIC)
- Placebo-controlled
- Pilot study
- Parallel murine model of septic DIC
Primary result
As reported in the abstract
Change in functional plasminogen
OctaplasLG®
+ 46
range as printed −96–118 · nM
Placebo
−84
range as printed −180–27 · nM
P < 0.05
Further findings
Mortality · non-significant trend
| Outcome | OctaplasLG® | Placebo | P value |
|---|---|---|---|
| Change in plasmin generation | 0.12 (range as printed −0.25–1.27) fmol | −0.36 (range as printed −1.58–0.12) fmol | P < 0.05 |
Plasmin-antiplasmin, PAI-1, tissue-type plasminogen activator
- No changes observed
Septic DIC mice vs controls: functional plasminogen and plasmin generation (murine model)
- Functional plasminogen, DIC mice vs controls (nM)
- 100 [66-126] vs. 295 [268-343]
- Plasmin generation, DIC mice vs controls (fmol, p < 0.05)
- 1.8 [1.4-2.1] vs. 3.0 [2.8-3.3]
- After plasminogen supplementation: plasminogen (nM)
- 346 [287; 360]
- After plasminogen supplementation: plasmin generation (fmol)
- 4.1 [3.7; 5.5]
Original publication
Plasminogen supplementation reverses fibrinolytic insufficiency in sepsis-induced disseminated intravascular coagulation: a pilot study. Intensive Care Med. Published 25 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →